Corcept Therapeutics Incorporated (CORT)
NASDAQ · Healthcare
Corcept Therapeutics Incorporated EBITDA 2009–2025
Corcept Therapeutics Incorporated annual/quarterly ebitda history and growth rate from 2009 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Corcept Therapeutics Incorporated ebitda for the quarter ending March 31, 2026 was -49.0 M, a 1363.62% decrease year-over-year.
- Corcept Therapeutics Incorporated ebitda for the twelve months ending March 31, 2026 was -480000, a 100.46% decrease year-over-year.
- Corcept Therapeutics Incorporated annual ebitda for 2025 was 45.9 M, a 66.64% decrease from 2024.
- Corcept Therapeutics Incorporated annual ebitda for 2024 was 137.7 M, a 27.16% increase from 2023.
- Corcept Therapeutics Incorporated annual ebitda for 2023 was 108.3 M, a 4.89% decrease from 2022.
- Corcept Therapeutics Incorporated annual ebitda for 2022 was 113.9 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Corcept Therapeutics Incorporated EBITDA — FAQ
Corcept Therapeutics Incorporated (CORT) ebitda over the last 11 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CORT's ebitda history?
The chart and table above show Corcept Therapeutics Incorporated's ebitda by year and by quarter, including the growth rate.